CCL7

Summary

CCL7 (C-C motif chemokine ligand 7, HGNC:10634) is a protein-coding gene on chromosome 17q12, encoding C-C motif chemokine 7 (P80098). Chemotactic factor that plays an important role in immune regulation.

This gene encodes monocyte chemotactic protein 3, a secreted chemokine which attracts macrophages during inflammation and metastasis. It is a member of the C-C subfamily of chemokines which are characterized by having two adjacent cysteine residues. The protein is an in vivo substrate of matrix metalloproteinase 2, an enzyme which degrades components of the extracellular matrix. This gene is part of a cluster of C-C chemokine family members on chromosome 17q.

Source: NCBI Gene 6354 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 11 total
• Druggable target: yes
• MANE Select transcript: NM_006273

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:10634
Approved symbol	CCL7
Name	C-C motif chemokine ligand 7
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	MCP-3, NC28, FIC, MARC, MCP3
Ensembl gene	ENSG00000108688
Ensembl biotype	protein_coding
OMIM	158106
Entrez	6354

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 3 protein_coding

ENST00000378569, ENST00000394627, ENST00000394630

RefSeq mRNA: 1 — MANE Select: NM_006273 NM_006273

CCDS: CCDS11278

Canonical transcript exons

ENST00000378569 — 3 exons

Exon	Start	End
ENSE00000554506	34271146	34271263
ENSE00001855300	34271697	34272242
ENSE00001906093	34270221	34270366

Expression profiles

Bgee: expression breadth ubiquitous, 124 present calls, max score 75.78.

FANTOM5 (CAGE): breadth broad, TPM avg 14.4595 / max 2250.0791, expressed in 489 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160307	14.3956	488
160308	0.0639	27

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
frontal pole	UBERON:0002795	75.78	gold quality
type B pancreatic cell	CL:0000169	75.53	gold quality
paraflocculus	UBERON:0005351	74.67	gold quality
endometrium epithelium	UBERON:0004811	74.50	gold quality
olfactory bulb	UBERON:0002264	74.20	gold quality
middle frontal gyrus	UBERON:0002702	73.94	gold quality
islet of Langerhans	UBERON:0000006	72.69	gold quality
mucosa of urinary bladder	UBERON:0001259	71.27	silver quality
stromal cell of endometrium	CL:0002255	70.49	gold quality
hair follicle	UBERON:0002073	68.80	gold quality
amniotic fluid	UBERON:0000173	67.68	silver quality
cartilage tissue	UBERON:0002418	66.74	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	65.80	gold quality
cerebellar vermis	UBERON:0004720	64.59	gold quality
diaphragm	UBERON:0001103	63.64	gold quality
vermiform appendix	UBERON:0001154	63.36	gold quality
caecum	UBERON:0001153	62.68	gold quality
thymus	UBERON:0002370	62.49	gold quality
male germ cell	CL:0000015	62.39	gold quality
cervix squamous epithelium	UBERON:0006922	62.05	gold quality
Brodmann (1909) area 10	UBERON:0013541	61.38	gold quality
sperm	CL:0000019	60.99	gold quality
quadriceps femoris	UBERON:0001377	60.59	gold quality
oocyte	CL:0000023	60.42	gold quality
rectum	UBERON:0001052	60.30	gold quality
smooth muscle tissue	UBERON:0001135	60.28	gold quality
upper arm skin	UBERON:0004263	60.03	gold quality
vastus lateralis	UBERON:0001379	59.92	gold quality
gingival epithelium	UBERON:0001949	59.85	gold quality
lower lobe of lung	UBERON:0008949	59.63	silver quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.64

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AP1, BCL6, CTNNB1, ESR1, ETV5, ETV6, HAND2, HR, JUN, LEF1, STAT6, TRPV4

miRNA regulators (miRDB)

47 targeting CCL7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-4500	99.99	72.72	2367
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-380-3P	99.89	70.18	1978
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-4760-5P	99.80	69.88	1619

Literature-anchored findings (GeneRIF, showing 40)

• The two most abundant alleles of the CA/GA microsatellite polymorphism in the promoter-enhancer region of the MCP-3 gene, A2 and A3, are significantly associated with multiple sclerosis in the Belgian case-control study, but not in the family study. (PMID:12127674)
• overexpression of MCP-3 in early-stage systemic sclerosis suggests a novel role for this protein as a fibrotic mediator activating extracellular matrix gene expression in addition to promoting leukocyte trafficking. (PMID:12847692)
• monocyte chemotactic protein-3 uses a different mode of action from eotaxin (PMID:14733956)
• data suggest that cyclic mechanical stretch of the uterine cervix by the presenting part of the fetus during labour may augment both IL-8 and MCP-3 production in the uterine cervix via AP-1 activation. (PMID:15194816)
• These results suggest that oxLDL delivers its signal for MCP-3 expression via PPARgamma, which may be further related to the atherogenesis. (PMID:15381085)
• A non-heparin-binding mutant CCL7 inhibits chemotactic potential of synovial fluid from patients with active rheumatoid arthritis and demonstrates the glycosaminoglycan-binding requirement for chemokine-driven inflammation in vivo (PMID:16002730)
• CCR8 ligands are allotropic, binding to distinct sites within CCR8; the human immune system may have evolved to use CCL7 as a selective antagonist of viral chemokine activity at CCR8 but not those of the host ligand (PMID:17023422)
• MCP-3 is critical for monocyte mobilization and suggests new roles for monocyte chemoattractants in leukocyte homeostasis. (PMID:17364026)
• CCL7 synergizes with coproduced CXCL8 in peripheral blood monocyte migration. (PMID:18469140)
• The expression of MCP-3 in laryngeal squamous cell carcinoma is much higher than in normal tissue. (PMID:18533557)
• MMP-12 truncates and inactivates ELR+ CXC chemokines and generates CCL2, -7, -8, and -13 antagonists (PMID:18660381)
• IL-12 p35, ICAM-1 and MCP-3 mRNAs are expressed in primary nasal epithelial cells. (PMID:19253530)
• increased plasma levels in patients with amnestic mild cognitive impairment (PMID:19403065)
• High MCP-3 is associated with macrophage/microglia infiltration in gliomas. (PMID:19424580)
• higher expression in the genital mucosa than in the blood of HIV-1-infected women from Benin (PMID:19898927)
• Elevated level of CCL7 is associated with invasion and migration of oral squamous cell carcinoma. (PMID:19937793)
• Monocyte chemoattractant protein-3 (MCP-3) was highly expressed in patients with chronic periodontitis, particularly in those with progressive periodontal lesions. (PMID:20151806)
• Cytoplasmic GR interacts with a subset of CCL7 mRNA through specific sequences and can regulate turnover rates, a novel posttranscriptional role for GR as an RNA-binding protein. (PMID:21148795)
• Basal monocyte migration may be facilitated by the astrocyte-derived cytokine CCL7 whose production is rapidly increased by TNF-alpha and thus likely plays a critical role in initiating neuroinvasion by SIV/HIV. (PMID:21279498)
• Data show that, for the small macrophages in COPD, increased transcript and protein levels for CCL2, CCL7, CCL13 and CCL22 with a more than 100-fold increase for CCL13 mRNA. (PMID:21327296)
• we established, for the first time, a significant association of MCP3 variants with atopic asthma. (PMID:21388664)
• MCP-3 is produced by human coronary artery smooth muscle cells and directly induces CASMC proliferation in vitro, suggesting a potential role for this chemokine in vascular pathology (PMID:21536288)
• These results suggest that overexpression of CCL21 and CCL7 is associated with tumor metastasis and serves as a prognostic factor in patients with gastric cancer. (PMID:22468089)
• Immunohistochemistry and real-time PCR analysis showed that CCL7 was expressed in normal colonic epithelium and the expression was higher in liver metastases compared to primary CRC. (PMID:22614322)
• Systemic IFN-gamma triggered the secretion of C-C motif ligand chemokines CCL2 and CCL7 leading to the egress of early, myeloid-committed progenitors from the bone marrow mediated by their common receptor CCR2. (PMID:23762028)
• Anticancer effect of desmethyl-lasiodiplodin is mediated, in part, by upregulation of apoptotic genes and downregulation of MCP-3. (PMID:23764760)
• Our data demonstrate that the monocyte-specific chemokine CCL7 and its receptor CCR2 are expressed in tumour cells of RCC (PMID:24327013)
• Overexpression of ISL1 in human mesnchymal stem cells promotes angiogenesis in vitro and in vivo through increasing secretion of MCP3 and other paracrine factors. (PMID:24578274)
• Data indicate that different glycosaminoglycan-binding properties of monocyte chemoattractant protein-3/CCL7 and monocyte chemoattractant protein (MCP)-1/CCL2 suggest non-redundant functions and regulation. (PMID:24727473)
• These results suggest that let-7d may suppress renal cell carcinoma growth, metastasis, and tumor macrophage infiltration at least partially through targeting COL3A1 and CCL7. (PMID:25193015)
• Based on nasopharyngeal CCL7 gene expression in readily available Nasopharyngeal aspirate samples , we can discriminate between severity of disease in Respiratory syncytial virus infected infants. (PMID:25261323)
• Periprostatic adipocytes drive prostate cancer progression in obesity via CCL7 secretion which stimulates CCR3 expressing tumor cells. (PMID:26756352)
• Enzyme-linked immunosorbent assay was used to detect the levels of chemokine (C-X-C motif) ligand 12, chemokine (C-X-C motif) ligand 7, hepatocyte growth factor, and fibroblast growth factor 1 in the supernatants of the laryngeal squamous cell carcinoma and control cells. (PMID:28475003)
• Higher expression of CCL7 receptor CCR2 (C-C chemokine receptor type 2) was associated with shorter overall survival of colorectal cancer patients. (PMID:30764543)
• Via a novel post-translational modification called Fic-mediatedadenylylation/AMPylation. (PMID:31034889)
• REVIEW: CCL7 Signaling in the Tumor Microenvironment (PMID:32060844)
• The chemokine CCL7 regulates invadopodia maturation and MMP-9 mediated collagen degradation in liver-metastatic carcinoma cells. (PMID:32217106)
• CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer. (PMID:33257678)
• Scoring cytokine storm by the levels of MCP-3 and IL-8 accurately distinguished COVID-19 patients with high mortality. (PMID:33318472)
• The increased intrathecal expression of the monocyte-attracting chemokines CCL7 and CXCL12 in tick-borne encephalitis. (PMID:33876413)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cxcl32b.1	ENSDARG00000071499
mus_musculus	Ccl7	ENSMUSG00000035373
rattus_norvegicus	Ccl7	ENSRNOG00000000239

Paralogs (26): CX3CL1 (ENSG00000006210), CCL26 (ENSG00000006606), CCL22 (ENSG00000102962), CCL17 (ENSG00000102970), CCL24 (ENSG00000106178), CCL2 (ENSG00000108691), CCL8 (ENSG00000108700), CCL1 (ENSG00000108702), CCL20 (ENSG00000115009), CCL25 (ENSG00000131142), CCL21 (ENSG00000137077), XCL1 (ENSG00000143184), XCL2 (ENSG00000143185), CCL11 (ENSG00000172156), CCL19 (ENSG00000172724), CCL13 (ENSG00000181374), CCL5 (ENSG00000271503), CCL23 (ENSG00000274736), CCL16 (ENSG00000275152), CCL4 (ENSG00000275302), CCL18 (ENSG00000275385), CCL15 (ENSG00000275718), CCL4L2 (ENSG00000276070), CCL3L3 (ENSG00000276085), CCL14 (ENSG00000276409), CCL3 (ENSG00000277632)

Protein

Protein identifiers

C-C motif chemokine 7 — P80098 (reviewed: P80098)

Alternative names: Monocyte chemoattractant protein 3, Monocyte chemotactic protein 3, NC28, Small-inducible cytokine A7

All UniProt accessions (3): P80098, A8MVH1, A8MX17

UniProt curated annotations — full annotation on UniProt →

Function. Chemotactic factor that plays an important role in immune regulation. Attracts monocytes, eosinophils, basophils, and T-cells to sites of inflammation or infection. Upon binding to various chemokine receptors including CCR1, CCR2, CCR3, and CCR5, facilitates immune cell migration by guiding them to infected tissues. Interacts with CCR2 to facilitate the release of monocytes from the bone marrow into the bloodstream, maintaining monocyte homeostasis. In turn, monocytes recruited to inflamed or injured tissues can differentiate into macrophages or dendritic cells, which are essential for immune defense and tissue repair. Through CCR1, contributes to macrophage polarization via NF-kappa-B activation which leads to the release of inflammatory factors. In the trigeminal ganglion neurons, activates ERK via CCR2 and CCR3 to enhance neuronal excitability, which contributes to the maintenance of trigeminal neuropathic pain. Additionally, modulates the early immune response in the skin, preventing pathogen dissemination while maintaining cutaneous immune control.

Subunit / interactions. Monomer. Interacts with TNFAIP6 (via Link domain).

Subcellular location. Secreted.

Post-translational modifications. O-glycosylated.

Similarity. Belongs to the intercrine beta (chemokine CC) family.

RefSeq proteins (1): NP_006264* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000827	Chemokine_CC_CS	Conserved_site
IPR001811	Chemokine_IL8-like_dom	Domain
IPR036048	Interleukin_8-like_sf	Homologous_superfamily
IPR039809	Chemokine_b/g/d	Family

Pfam: PF00048

UniProt features (20 total): strand 6, helix 3, mutagenesis site 3, sequence conflict 2, disulfide bond 2, signal peptide 1, chain 1, modified residue 1, glycosylation site 1

Structure

Experimental structures (PDB)

10 structures.

PDB	Method	Resolution (Å)
8FK6	X-RAY DIFFRACTION	1.74
7S58	X-RAY DIFFRACTION	1.82
7SCU	X-RAY DIFFRACTION	1.86
8FK8	X-RAY DIFFRACTION	1.96
8FJ3	X-RAY DIFFRACTION	2.07
7S59	X-RAY DIFFRACTION	2.39
4ZKC	X-RAY DIFFRACTION	3.15
8JPS	ELECTRON MICROSCOPY	3.65
1BO0	SOLUTION NMR
1NCV	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P80098-F1	85.93	0.61

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 24

Disulfide bonds (2): 34–59, 35–75

Glycosylation sites (1): 29

Mutagenesis-validated functional residues (3):

Position	Phenotype
41	decreases binding to link domain of tnfaip6; when associated with a-42 and a-45.
42	decreases binding to link domain of tnfaip6; when associated with a-41 and a-45.
45	decreases binding to link domain of tnfaip6; when associated with a-41 and a-42.

Function

Pathways and Gene Ontology

Reactome pathways

6 pathways

ID	Pathway
R-HSA-380108	Chemokine receptors bind chemokines
R-HSA-162582	Signal Transduction
R-HSA-372790	Signaling by GPCR
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-500792	GPCR ligand binding

MSigDB gene sets: 319 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_UP, MODULE_92, GOBP_RESPONSE_TO_ETHANOL, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_ANTIMICROBIAL_HUMORAL_RESPONSE, GRUETZMANN_PANCREATIC_CANCER_DN, GOBP_REGULATION_OF_CELL_MORPHOGENESIS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, GOBP_CELL_CHEMOTAXIS, GOBP_INFLAMMATORY_RESPONSE, GOBP_RESPONSE_TO_PEPTIDE, ENK_UV_RESPONSE_KERATINOCYTE_UP, MODULE_64, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_RESPONSE_TO_MC_AND_SERUM_DEPRIVATION_UP

GO Biological Process (20): monocyte chemotaxis (GO:0002548), intracellular calcium ion homeostasis (GO:0006874), chemotaxis (GO:0006935), inflammatory response (GO:0006954), cytoskeleton organization (GO:0007010), signal transduction (GO:0007165), cell-cell signaling (GO:0007267), regulation of cell shape (GO:0008360), response to gamma radiation (GO:0010332), positive regulation of cell migration (GO:0030335), eosinophil chemotaxis (GO:0048245), positive regulation of inflammatory response (GO:0050729), antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844), chemokine-mediated signaling pathway (GO:0070098), cellular response to ethanol (GO:0071361), positive regulation of natural killer cell chemotaxis (GO:2000503), immune response (GO:0006955), canonical NF-kappaB signal transduction (GO:0007249), signal transduction involved in regulation of gene expression (GO:0023019), negative regulation of cytokine production involved in inflammatory response (GO:1900016)

GO Molecular Function (7): chemokine activity (GO:0008009), heparin binding (GO:0008201), CCR1 chemokine receptor binding (GO:0031726), CCR2 chemokine receptor binding (GO:0031727), CCR chemokine receptor binding (GO:0048020), cytokine activity (GO:0005125), protein binding (GO:0005515)

GO Cellular Component (2): extracellular region (GO:0005576), obsolete extracellular space (GO:0005615)

Reactome top-level categories

Rollup of top-5 pathways:

Category	Pathways
Peptide ligand-binding receptors	1
Signal Transduction	1
GPCR ligand binding	1
Class A/1 (Rhodopsin-like receptors)	1
Signaling by GPCR	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	2
signaling	2
chemokine receptor binding	2
CCR chemokine receptor binding	2
leukocyte chemotaxis	1
mononuclear cell migration	1
myeloid leukocyte migration	1
intracellular monoatomic cation homeostasis	1
calcium ion homeostasis	1
response to chemical	1
taxis	1
defense response	1
organelle organization	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
regulation of cell morphogenesis	1
regulation of biological quality	1
response to ionizing radiation	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
granulocyte chemotaxis	1
eosinophil migration	1
inflammatory response	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
regulation of inflammatory response	1
antimicrobial humoral response	1
G protein-coupled receptor signaling pathway	1
cytokine-mediated signaling pathway	1
cellular response to chemokine	1
response to ethanol	1
cellular response to alcohol	1
natural killer cell chemotaxis	1
positive regulation of lymphocyte chemotaxis	1
regulation of natural killer cell chemotaxis	1
immune system process	1
response to stimulus	1
intracellular signaling cassette	1

Protein interactions and networks

STRING

1328 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCL7	CCR2	P41597	997
CCL7	CCR1	P32246	996
CCL7	CCR3	P51677	996
CCL7	CCR5	P51681	994
CCL7	CXCL8	P10145	881
CCL7	CX3CL1	P78423	869
CCL7	ACKR2	O00590	869
CCL7	A0A0J9YW77	A0A0J9YW77	865
CCL7	CXCR2	P25025	853
CCL7	CXCL1	P09341	847
CCL7	CCL27	Q9Y4X3	831
CCL7	CCL23	P55773	827
CCL7	CXCL9	Q07325	820
CCL7	CCL19	Q99731	800
CCL7	TNF	P01375	795

IntAct

17 interactions, top by confidence:

A	B	Type	Score
	CCL7	psi-mi:“MI:0407”(direct interaction)	0.620
UBQLN1	CCL7	psi-mi:“MI:0915”(physical association)	0.560
CCL7	UBQLN1	psi-mi:“MI:0915”(physical association)	0.560
CCL7	UBQLN2	psi-mi:“MI:0915”(physical association)	0.560
CCL7	XCL2	psi-mi:“MI:0407”(direct interaction)	0.440
CCL7	CXCL6	psi-mi:“MI:0407”(direct interaction)	0.440
CCL7	UBQLN2	psi-mi:“MI:0915”(physical association)	0.000
CCL7	FEZ1	psi-mi:“MI:0915”(physical association)	0.000
CCL7	TLE5	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (17): UBQLN1 (Two-hybrid), FEZ1 (Two-hybrid), UBQLN2 (Two-hybrid), CCL7 (Co-crystal Structure), CCL7 (Two-hybrid), CCL7 (Reconstituted Complex), CCL7 (Biochemical Activity), CCL7 (Affinity Capture-Western), CXCL6 (Reconstituted Complex), XCL2 (Reconstituted Complex), CCL7 (Positive Genetic), CCL7 (Reconstituted Complex), CCL7 (Reconstituted Complex), CCL7 (Reconstituted Complex), CCL7 (Affinity Capture-RNA)

ESM2 similar proteins: F5HET8, O00626, O88430, O89093, P08317, P10889, P12850, P13500, P14095, P19874, P28291, P30348, P36925, P42830, P42831, P46653, P49873, P51671, P52203, P55774, P61274, P61275, P78556, P80075, P80098, P80221, P82943, Q03366, Q09141, Q16627, Q5RA36, Q62401, Q68AY9, Q68Y88, Q6W5C0, Q8HYP8, Q8HYP9, Q8I021, Q8MIT7, Q8SQB1

Diamond homologs: F5HET8, O00175, O00585, O00626, O55145, O88430, O97919, P10147, P10148, P10855, P13236, P13500, P13501, P14097, P14844, P16619, P27784, P28291, P28292, P30882, P42831, P46632, P47993, P49873, P50229, P50230, P50231, P51670, P51671, P52203, P55773, P55774, P61274, P61275, P78423, P80075, P80098, P80343, P82943, P97272

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
CCL7	up-regulates	CCR1	binding
CCL7	up-regulates	Macrophage_activation
IFNAR	“up-regulates quantity by expression”	CCL7
Macrophage_activation	“up-regulates quantity”	CCL7

Disease & clinical

Clinical variants and AI predictions

ClinVar

11 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	11
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

266 predictions. Top by Δscore:

Variant	Effect	Δscore
17:34271253:G:GT	donor_gain	1.0000
17:34271253:G:T	donor_gain	1.0000
17:34271256:GCT:G	donor_gain	1.0000
17:34271264:G:GG	donor_gain	1.0000
17:34271692:CACA:C	acceptor_loss	1.0000
17:34271693:ACAG:A	acceptor_loss	1.0000
17:34271694:CAGC:C	acceptor_loss	1.0000
17:34271695:A:AG	acceptor_gain	1.0000
17:34271695:AGCTT:A	acceptor_loss	1.0000
17:34271696:G:A	acceptor_loss	1.0000
17:34271696:G:GA	acceptor_gain	1.0000
17:34270362:GCCAG:G	donor_gain	0.9900
17:34271259:GTAAT:G	donor_gain	0.9900
17:34271687:T:TA	acceptor_gain	0.9900
17:34271694:C:G	acceptor_gain	0.9900
17:34271696:GC:G	acceptor_gain	0.9900
17:34271696:GCT:G	acceptor_gain	0.9900
17:34271696:GCTT:G	acceptor_gain	0.9900
17:34271696:GCTTC:G	acceptor_gain	0.9900
17:34270364:CAGGT:C	donor_loss	0.9800
17:34270365:AGGTA:A	donor_loss	0.9800
17:34270368:TAAGG:T	donor_loss	0.9800
17:34271144:A:AG	acceptor_gain	0.9800
17:34271145:G:GG	acceptor_gain	0.9800
17:34271693:A:AG	acceptor_gain	0.9800
17:34271139:A:AG	acceptor_gain	0.9600
17:34271144:AGTTG:A	acceptor_gain	0.9600
17:34271145:GTT:G	acceptor_gain	0.9600
17:34271145:GTTGG:G	acceptor_gain	0.9600
17:34271697:CTTCA:C	acceptor_gain	0.9500

AlphaMissense

648 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:34271748:G:C	W82C	0.981
17:34271748:G:T	W82C	0.981
17:34271699:T:C	F66S	0.969
17:34271746:T:A	W82R	0.950
17:34271746:T:C	W82R	0.950
17:34271699:T:G	F66C	0.939
17:34271750:T:A	V83D	0.925
17:34271725:T:A	C75S	0.922
17:34271726:G:C	C75S	0.922
17:34271728:G:C	A76P	0.919
17:34271244:T:A	C59S	0.918
17:34271245:G:C	C59S	0.918
17:34271244:T:C	C59R	0.916
17:34271220:T:G	Y51D	0.901
17:34271725:T:C	C75R	0.901
17:34271172:T:A	C35S	0.897
17:34271173:G:C	C35S	0.897
17:34271729:C:A	A76D	0.895
17:34271246:T:G	C59W	0.887
17:34271172:T:C	C35R	0.882
17:34271749:G:C	V83L	0.880
17:34271726:G:A	C75Y	0.877
17:34271727:T:G	C75W	0.877
17:34271260:T:A	V64E	0.875
17:34271197:T:C	I43T	0.863
17:34271245:G:A	C59Y	0.862
17:34271212:T:A	L48Q	0.860
17:34271698:T:C	F66L	0.850
17:34271700:C:A	F66L	0.850
17:34271700:C:G	F66L	0.850

dbSNP variants (sampled 300 via entrez): RS1000045109 (17:34269532 T>C), RS1001040406 (17:34272004 G>A), RS1001717241 (17:34268347 T>C), RS1002017945 (17:34270718 G>C,T), RS1002070512 (17:34270959 T>C), RS1002262353 (17:34272366 A>T), RS1002605020 (17:34272588 T>C,G), RS1002742914 (17:34268434 A>G), RS1004987699 (17:34269736 T>C,G), RS1005036493 (17:34269891 A>T), RS1005987629 (17:34268458 T>A), RS1006453974 (17:34268796 G>C), RS1006555520 (17:34268860 C>A,T), RS1006627446 (17:34268647 G>A,C,T), RS1008783706 (17:34270002 T>C)

Disease associations

OMIM: gene MIM:158106 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000879_61	Crohn’s disease	2.000000e-13
GCST001438_14	Crohn’s disease	4.000000e-08
GCST003854_13	Gut microbiota (functional units)	5.000000e-07
GCST003854_15	Gut microbiota (functional units)	6.000000e-07
GCST004131_81	Inflammatory bowel disease	1.000000e-12
GCST004132_101	Crohn’s disease	2.000000e-17
GCST006585_389	Blood protein levels	2.000000e-263

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007874	gut microbiome measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3217391 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

54 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Lipopolysaccharides	affects cotreatment, affects response to substance, increases expression, decreases reaction, increases secretion	3
sodium arsenite	affects expression, increases expression	2
nickel chloride	decreases secretion, affects cotreatment, increases secretion, decreases reaction, increases expression	2
Atrazine	affects cotreatment, increases expression	2
Calcium	increases uptake, decreases reaction	2
Nickel	increases expression	2
Tretinoin	increases expression, affects cotreatment	2
ferric oxide	increases secretion	1
propionaldehyde	increases expression	1
bisphenol A	increases expression	1
2,5,2’,5’-tetrachlorobiphenyl	decreases expression	1
2,4,5,2’,4’,5’-hexachlorobiphenyl	increases expression	1
butyraldehyde	increases expression	1
perfluorooctanoic acid	decreases expression, decreases secretion	1
chromic oxide	increases secretion	1
manganese chloride	increases expression	1
4-phenylenediamine	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	increases expression	1
acetovanillone	decreases reaction, increases expression	1
perfluorooctane sulfonic acid	decreases secretion, decreases expression	1
CGP 52608	affects binding, increases reaction	1
PCB 180	affects expression	1
lipopolysaccharide, E. coli O26-B6	increases expression, decreases reaction	1
diphenylarsinic acid	increases secretion	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
abexinostat	decreases expression	1
2’-hydroxyflavanone	increases secretion, decreases reaction	1
manganese ferrite	increases secretion	1
Arsenic Trioxide	affects cotreatment, increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3227327	Binding	Inhibition of CCL7 in human THP1 cells assessed as reduction of cell migration at 50 uM after 3 hrs	Evaluation of two cyclic di-peptides as inhibitors of CCL2 induced chemotaxis — Medchemcomm

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.